Literature DB >> 29404351

Trends, predictors and outcomes of ischemic stroke and intracranial hemorrhage in patients with a left ventricular assist device.

Muhammad Shahreyar1,2, Tamunoinemi Bob-Manuel1, Rami N Khouzam1,2, Mohammad W Bashir3, Samian Sulaiman4, Oluwaseun Akinseye1,2, Arindam Sharma1, April Carter1, Samuel Latham1, Sanjay Bhandari4, Arshad Jahangir5,6.   

Abstract

BACKGROUND: Patients with a left ventricular assist device (LVAD) are at a higher risk of ischemic stroke (IS) and intracranial hemorrhage (ICH). There is limited data available on risk factors and outcomes associated with IS and ICH in LVAD patients.
METHODS: All patients >18 years of age with an LVAD were identified based on the U.S. Nationwide Inpatient Sample (NIS) database from the year 2007 to 2011. Patients with a discharge diagnosis of IS were compared to those without IS. In a separate analysis, patients with a discharge diagnosis of ICH were compared to patients without ICH. Trends, predictors and outcomes of IS and ICH were analyzed using a multivariate regression model.
RESULTS: Out of 17,323 discharges with a primary diagnosis of heart failure with LVAD, 624 (3.6%) patients had a co-diagnosis of IS and 387 (2.2%) had a co-diagnosis of ICH. From 2007 to 2011, the discharge diagnosis of heart failure with LVAD increased from 946 to 5,540, but the proportion of patients with IS remained about 3.4%, while the incidence of ICH decreased from 3.8% in 2007 to a plateau of around 2.2% in the following years. After adjusting for potential confounders, increasing Charlson Comorbidity Index (CCI) score was an independent predictor of IS and ICH. In-hospital mortality was four-fold higher in the IS group (odds ratio: 4.2; 95% CI: 2.3-7.6; P<0.0001) and 18-fold higher in the ICH group (OR: 18; 95% CI: 9-34, P<0.0001). Renal disease (OR: 5.3; CI: 1.3-22.1; P=0.02), liver disease (OR: 4.9; CI: 1.1-21.2; P=0.03) and abnormal coagulation profile (OR: 4.8; CI: 1.6-14.4; P=0.01) were independent predictors of mortality in LVAD patients with IS. Presence of diabetes mellitus (OR 4.3, P=0.1) and liver disease (or 2.8, P=0.2) showed trends towards predicting mortality in LVAD patients with ICH but did not reach statistical significance.
CONCLUSIONS: Increasing comorbidity burden significantly increases the risk of both IS and ICH with LVAD. In our cohort, the incidence of IS and ICH increases the mortality 4- and 18-fold, respectively. Renal disease, liver disease and abnormal coagulation profile were independent predictors of mortality in LVAD patients with IS.

Entities:  

Keywords:  Left ventricular assist device (LVAD); heart failure; intracranial hemorrhage (ICH); ischemic stroke (IS); mortality

Year:  2018        PMID: 29404351      PMCID: PMC5787721          DOI: 10.21037/atm.2017.12.23

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  29 in total

Review 1.  Bleeding and thrombosis in patients with continuous-flow ventricular assist devices.

Authors:  Peter M Eckman; Ranjit John
Journal:  Circulation       Date:  2012-06-19       Impact factor: 29.690

2.  Sixth INTERMACS annual report: a 10,000-patient database.

Authors:  James K Kirklin; David C Naftel; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Marissa A Miller; J T Baldwin; J Timothy Baldwin; James B Young
Journal:  J Heart Lung Transplant       Date:  2014-04-21       Impact factor: 10.247

3.  Rise of the machines--left ventricular assist devices as permanent therapy for advanced heart failure.

Authors:  James C Fang
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

4.  Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study.

Authors:  R L Sacco; B Boden-Albala; R Gan; X Chen; D E Kargman; S Shea; M C Paik; W A Hauser
Journal:  Am J Epidemiol       Date:  1998-02-01       Impact factor: 4.897

5.  Stroke After Left Ventricular Assist Device Implantation: Outcomes in the Continuous-Flow Era.

Authors:  Laura Harvey; Christopher Holley; Samit S Roy; Peter Eckman; Rebecca Cogswell; Kenneth Liao; Ranjit John
Journal:  Ann Thorac Surg       Date:  2015-06-09       Impact factor: 4.330

6.  Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices.

Authors:  Jennifer A Frontera; Randall Starling; Sung-Min Cho; Amy S Nowacki; Ken Uchino; M Shazam Hussain; Maria Mountis; Nader Moazami
Journal:  J Heart Lung Transplant       Date:  2016-12-23       Impact factor: 10.247

7.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

8.  Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients.

Authors:  James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; J T Baldwin; J Timothy Baldwin; James B Young
Journal:  J Heart Lung Transplant       Date:  2013-02       Impact factor: 10.247

9.  Cerebrovascular accidents in patients with a ventricular assist device.

Authors:  Hiroyuki Tsukui; Adib Abla; Jeffrey J Teuteberg; Dennis M McNamara; Michael A Mathier; Linda M Cadaret; Robert L Kormos
Journal:  J Thorac Cardiovasc Surg       Date:  2007-06-04       Impact factor: 5.209

10.  Thromboembolic stroke in patients with a HeartMate-II left ventricular assist device - the role of anticoagulation.

Authors:  Walter M van den Bergh; Annemieke Oude Lansink-Hartgring; Abram L van Duijn; Annemarie E Engström; Jaap R Lahpor; Arjen J C Slooter
Journal:  J Cardiothorac Surg       Date:  2015-10-15       Impact factor: 1.637

View more
  9 in total

Review 1.  Neurocritical Care of Mechanical Circulatory Support Devices.

Authors:  Aaron Shoskes; Glenn Whitman; Sung-Min Cho
Journal:  Curr Neurol Neurosci Rep       Date:  2021-03-10       Impact factor: 5.081

2.  Bleeding in critical care associated with left ventricular assist devices: pathophysiology, symptoms, and management.

Authors:  F W G Leebeek; R Muslem
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD).

Authors:  Kazuki Nakagita; Kyoichi Wada; Yutaro Mukai; Takaya Uno; Ryoji Nishino; Sachi Matsuda; Hiromi Takenaka; Nobue Terakawa; Akira Oita; Mitsutaka Takada
Journal:  Eur J Clin Pharmacol       Date:  2018-05-21       Impact factor: 2.953

4.  Observation on the Nursing Effect of the Whole Process in Patients with Severe Intracranial Hemorrhage.

Authors:  Zhongwei Su; Wei Guo; Yun Luo; Yao Wang; Yue Du
Journal:  Comput Math Methods Med       Date:  2022-07-04       Impact factor: 2.809

5.  Coriolus versicolor polysaccharides (CVP) regulates neuronal apoptosis in cerebral ischemia-reperfusion injury via the p38MAPK signaling pathway.

Authors:  Lei Li; Yan Li; Cheng Miao; Yi Liu; Rui Liu
Journal:  Ann Transl Med       Date:  2020-09

6.  Ulinastatin alleviates cerebral ischemia-reperfusion injury in rats by activating the Nrf-2/HO-1 signaling pathway.

Authors:  Lei Cui; Wei Cao; Yanmin Xia; Xiaofang Li
Journal:  Ann Transl Med       Date:  2020-09

7.  Repetitive Ballistic Movements as a High-Risk Comorbidity in a Ventricular Assist Device Patient.

Authors:  Derek Pyland; Eric M Davis; Mark Quigg
Journal:  Neurol Clin Pract       Date:  2021-02

8.  Incidence and impact of ischemic and hemorrhagic stroke after left ventricular assist device implantation: A nationwide study.

Authors:  Samarthkumar Thakkar; Chintan Rupareliya; Rajkumar Doshi
Journal:  Indian Heart J       Date:  2019-09-13

9.  On the Optimization of a Centrifugal Maglev Blood Pump Through Design Variations.

Authors:  Peng Wu; Jiadong Huo; Weifeng Dai; Wei-Tao Wu; Chengke Yin; Shu Li
Journal:  Front Physiol       Date:  2021-06-18       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.